Exactech sees expiration of DPA; Pronota brings Genzyme alum on as CBO;

@FierceMedDev: Sony targets Israeli medical technologies--Globes. Item | Follow @FierceMedDev

> Gainesville, FL-based Exactech ($EXAC), which develops bone and joint restoration products, has seen the expiration of the deferred prosecution agreement it entered in December 2010 with the United States Attorney's Office for the District of New Jersey. Exactech release

> Belgian diagnostics company Pronota has named Carol Greve-Philips as chief business officer and Els Hubloux as CFO. Greve-Philips joins Pronota from Genzyme, where she was VP of corporate development. Pronota release

> Integra LifeSciences Holdings Corp ($IART) has launched the Integra Miltex veterinary orthopedic implant line, which includes plates, screws, lateral suturing products and instruments that aid in the repair of torn cruciate ligaments and broken or fractured bones in companion animals. Integra release

> The National Research Council of Canada - Industrial Research Assistance Program has approved funding of up to $107,000 to help Arch Biopartners develop diagnostic imaging applications for its brain tumor initiating cell targeting technology. Arch release

> The FDA's Center for Devices and Radiological Health has completed its review of Sunshine Heart's ($SSH) investigational device exemption for the C-Pulse Heart Assist System feasibility trial. The FDA has notified Sunshine that no other information is required at this time. Sunshine release

And Finally... A U.K. company has produced a computer chip that can connect traffic lights, parking meters and medical devices to the Internet. News

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.